Leaderboards/Hepatocellular Carcinoma Treatment and Prognosis

Hepatocellular Carcinoma Treatment and Prognosis

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Harriet Rumgay
Centre international de recherche sur le cancer
2
Xupeng Yang
Ministry of Education
3
Ziwei Guo
Lincoln University
4
Huanhuan Chong
Ruijin Hospital
5
Anuja Gajanan Magar
Hallym University
6
Qianru Li
Hangzhou Medical College
7
R.S. Finn
University of California, Los Angeles
8
Tamer A. Addissouky
University of Babylon
9
Gregor Laimer
Innsbruck Medical University
10
Shao-Hua Li
Sun Yat-sen University

Papers

1
Precision treatment in advanced hepatocellular carcinoma
Cancer Cell|2024
393 cit.
2
A Molecular Perspective on HIF-1α and Angiogenic Stimulator Networks and Their Role in Solid Tumors: An Update
International Journal of Molecular Sciences|2024
108 cit.
3
Global burden of oral cancer in 2022 attributable to smokeless tobacco and areca nut consumption: a population attributable fraction analysis
The Lancet Oncology|2024
97 cit.
4
Publication in Bulletin of the National Research Centre/Bulletin of the National Research Center (2024) [91 citations, W4391068193]
Bulletin of the National Research Centre/Bulletin of the National Research Center|2024
91 cit.
5
Global epidemiology of liver cancer 2022: An emphasis on geographic disparities
Chinese Medical Journal|2024
87 cit.
6
Publication in Egyptian Liver Journal (2024) [80 citations, W4390500385]
Egyptian Liver Journal|2024
80 cit.
7
Disparities in 36 cancers across 185 countries: secondary analysis of global cancer statistics
Frontiers of Medicine|2024
80 cit.
8
Publication in Scientific Reports (2025) [76 citations, W4408062005]
Scientific Reports|2025
76 cit.
9
Publication in Bulletin of the National Research Centre/Bulletin of the National Research Center (2024) [37 citations, W4394961439]
Bulletin of the National Research Centre/Bulletin of the National Research Center|2024
37 cit.
10
Publication in Journal of Clinical Cardiology (2024) [36 citations, W4390616573]
Journal of Clinical Cardiology|2024
36 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Christina Fitzmaurice
Gundersen Health System
2
Meritxell Huch
Center for Systems Biology Dresden
3
Lysiane Marthey
Université Paris-Saclay
4
Gudrun Maria Waaler Bjørnelv
Oslo University Hospital
5
Leonid Barkhatov
Haukeland University Hospital
6
Ronny Kristiansen
Oslo University Hospital
7
Nikolaos Andreatos
Washington University in St. Louis
8
Milan Milliner
Hôpitaux Universitaires Henri-Mondor
9
Nicolò Rigamonti
Vita-Salute San Raffaele University
10
David Hsiehchen
The University of Texas Southwestern Medical Center

Papers

1
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
The Lancet|2023
488 cit.
2
RNF43/ZNRF3 loss predisposes to hepatocellular-carcinoma by impairing liver regeneration and altering the liver lipid metabolic ground-state
Nature Communications|2022
70 cit.
3
Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150
Gastroenterology|2023
52 cit.
4
The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial
Nature Communications|2024
36 cit.
5
Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma
Cancer Research Communications|2023
32 cit.
6
Mouse liver assembloids model periportal architecture and biliary fibrosis
Nature|2025
32 cit.
7
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers
Nature Cancer|2024
30 cit.
8
A Multispecific Anti-CD40 DARPin Construct Induces Tumor-Selective CD40 Activation and Tumor Regression
Cancer Immunology Research|2022
26 cit.
9
Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma
Hepatology|2023
23 cit.
10
Care pathways at end-of-life for cancer decedents: registry based analyses of the living situation, healthcare utilization and costs for all cancer decedents in Norway in 2009-2013 during their last 6 months of life
BMC Health Services Research|2022
19 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Jordi Bruix
Hospital Clínic de Barcelona
2
Ann‐Lii Cheng
National Taiwan University
3
Jean‐Nicolas Vauthey
The University of Texas MD Anderson Cancer Center
4
Masatoshi Makuuchi
Nagano Children's Hospital
5
Arun J. Sanyal
Virginia Commonwealth University
6
Masatoshi Kudo
Kindai University
7
Yuman Fong
City Of Hope National Medical Center
8
Norihiro Kokudo
National Center for Global Health and Medicine
9
Riad Salem
Northwestern University
10
Josep M. Llovet
Icahn School of Medicine at Mount Sinai

Papers

1
Sorafenib in Advanced Hepatocellular Carcinoma
New England Journal of Medicine|2008
13k cit.
2
The Clavien-Dindo Classification of Surgical Complications
Annals of Surgery|2009
11.3k cit.
3
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Hepatology|2005
10.7k cit.
4
Management of Hepatocellular Carcinoma: An Update Δσ
Hepatology|2011
8.1k cit.
5
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
New England Journal of Medicine|2020
7.2k cit.
6
Management of Hepatocellular Carcinoma *
Hepatology|2005
5.9k cit.
7
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
The Lancet Oncology|2008
5.8k cit.
8
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
The Lancet|2018
5.4k cit.
9
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Journal of Hepatology|2001
4.1k cit.
10
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Hepatology|2012
3.8k cit.

Reagents for Hepatocellular Carcinoma Treatment and Prognosis

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 66

HA-Tag (C29F4) Rabbit Monoclonal Antibody (Alexa Fluor® 700 Conjugate)

Cited in 7 papers
#17561$465
View Evidence →
Cell Signaling Technology

p57 Kip2 Antibody

Cited in 6 papers
#2557$136,317
View Evidence →
Agilent/Dako

Human Hepatocyte

Cited in 5 papers
#M7158
View Evidence →

🌟 All-Time

Most validated

Cell Signaling Technology

ChIP-Grade Protein G Magnetic Beads

Cited in 9 papers
#9006$243
View Evidence →
Cell Signaling TechnologyEvidence 63

GIRK2 (D6C2T) Rabbit Monoclonal Antibody

Cited in 8 papers
#25797$161,351
View Evidence →
Cell Signaling TechnologyEvidence 65

BATF (F2L7C) Rabbit Monoclonal Antibody

Cited in 7 papers
#30889$178,415
View Evidence →